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Abstract 
Several miRNAs have been reported to be associated with immunoglobulin heavy 
chain (IgH) mutation and ZAP-70 expression status in blood samples of B-cell 
chronic lymphocytic leukaemia/small lymphocytic lymphoma (B-CLL/SLL). In the 
bone marrow and lymphoid tissues, proliferation centres (PCs) represent an 
important site of activation and proliferation of the neoplastic cells, suggesting that 
these tissues better reflect the biology of CLL than circulating blood cells. We 
collected 33 lymph nodes and 37 blood CLL samples and analysed IgH mutation 
status and ZAP-70 expression status. Expression of 15 miRNAs was analysed by 
qRT-PCR and RNA-ISH. Sixty-three per cent of the lymph node cases contained 
mutated IgH genes and 49% of the lymph node cases were ZAP-70-positive, and a 
significant correlation was observed between ZAP-70 expression and IgH mutation 
status. Of the blood CLL samples, 49% contained mutated IgH sequences. The 
miRNA expression pattern in CLL lymph node and blood samples was very similar. 
Three of 15 miRNAs (miR-16, miR-21, and miR-150) showed a high expression 
level in both blood and lymph node samples. No difference was observed between 
ZAP-70-positive or -negative and between IgH-mutated or unmutated cases. No 
correlation was found between miR-15a and miR-16 expression levels and 13q14 
deletion in the blood CLL samples. RNA in situ hybridization (ISH) revealed strong 
homogeneous staining of miR-150 in the tumour cells outside the PCs. In reverse 
BIC/pri-miR-155 expression was observed mainly in individual cells including 
prolymphocytes of the PCs. This reciprocal pattern likely reflects the different 
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Introduction 
B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is 
characterized by the accumulation of mature CD5+, CD19+, CD23+ B-lymphocytes. 
From a prognostic point of view, CLL represents a heterogeneous disorder. Indolent 
versus aggressive forms of the disease can be discriminated by a magnitude of 
clinical, morphological, kinetic, immunophenotypic, cytogenetic, and molecular 
features [1,2]. In 1999, two reports [3,4] showed that CLL cases with unmutated IgH 
genes, ie homology of ≥98% with germline sequences, are associated with a more 
aggressive form. Later on, two reports [5,6] showed that CLL cases with unmutated 
IgH genes have a distinct gene expression profile with active signaing of the B-cell 
receptor (BCR) and are frequently ZAP-70-positive. 
In CLL, the so-called proliferation centres (PCs) can be found at the tissue level. 
These structures contain a slightly increased number of T-cells and in a few cases, 
also some dendritic cells. The neoplastic cells in these structures are more activated 
than the surrounding neoplastic cells and circulating cells, reflected by higher 
expression of a number of antigens including immunoglobulin, CD38, Ki67/MIB1, 
CD23, and MUM1/IRF4 [7,8]. One of the most common genomic aberrations in CLL 
is deletion of the 13q14 region. According to Calin et al [9], the miR-15a and miR-16-
1 polycistron is the most likely target in this genomic region. A homologous miRNA 
cluster is located at 3q26.1, which contains miR-15b and miR-16-2. Based on these 
initial observations, several groups have studied these and other miRNAs in B-CLL, 
other lymphomas, and normal B-cells, and it has become clear that miRNAs play a 
crucial role in lymphomagenesis. miR-15, miR-16, miR-21, miR-92, miR-101, miR-
150, miR-155, and miR-181a are all highly expressed in B-CLL [10–12]. miR-92 is a 
member of the miR-17-92 polycistron (miR-17-3p, miR-17-5p, miR-18a, miR-19a, 
miR-20a, miR-19b, miR-92a), which is located in the 13q31 region that frequently 
shows copy number gains or evenamplifications in various NHL subtypes [13,14].  
We have investigated miRNA expression in lymph node and blood CLL by qRT-PCR 
followed by RNA in situ hybridization (ISH) and show that miRNA expression levels 
are not correlated with ZAP-70, IgH mutation, and 13q14 deletion status. 
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Materials and methods 
CLL samples 
Formalin-fixed and paraffin-embedded tissue samples of 33 CLL cases were 
obtained from patients diagnosed with CLL in the Department of Pathology and 
Laboratory Medicine, University Medicine Centre Groningen. All protocols for 
obtaining and studying human tissues and cells were approved by the institution’s 
review board for human subject research. CLL diagnosis was based on clinical 
manifestation, blood leukocyte and lymphocyte counts, morphology and 
immunophenotyping in accordance with the WHO classification guidelines [15]. In 31 
cases, a leukaemic picture was present in addition to the lymphoma component. 
Two cases presented as lymphoma without a leukaemic picture in the blood. Thirty 
seven CLL blood samples were collected from the Department of Hematology, 
Erasmus MC, Rotterdam. These cases have previously been analysed for IgH 
mutation and 13q14 deletion status [16] (see Supplementary Tables 2 and 3). 
 
Immunohistochemistry of ZAP-70 
ZAP-70 immunohistochemistry was performed as previously described for the lymph 
node cases [8]. Immunostaining was performed using anti-ZAP-70 antibody (clone 
2F3.2; Upstate Biotechnology) at a dilution of 1:100. The tumour was considered 
strongly positive when the staining intensity was similar to that observed in T-cells, 
weakly positive when the staining intensity of the tumour cells was much less than 
the infiltrating T-cells, and negative when no staining was observed in the tumour 
cells. 
 
 Determination of IgH somatic hypermutations 
DNA was extracted from lymph node specimens using standard procedures and IgH 
amplification was carried out in duplicate, as described previously [17,18], including 
negative controls. PCR products were analyzed on MegaBase (Amersham 
Bioscience, Midland, Ontario, Canada). The PCR products containing one 
rearranged allele were spin column-purified (Qiagen, Valencia, CA, USA) and 
sequenced using dye terminator chemistry (Big Dye Kit; Applied Biosystems, Foster 
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City, CA, USA) on a genetic analyser model 377 (Applied Biosystems). If two peaks 
were observed, the PCR products were cloned and multiple clones were sequenced. 
Consensus IgH sequences were compared with the germline sequence using Ig-
BLAST (http://www.ncbi.nlm.nih.gov/igblast/). The consensus sequence with a 
functional open reading frame was used to determine the mutation status. Cases 
with homology of ≥98% with germline sequences were considered as unmutated, 
and cases with homologies <98% as mutated. 
 
TaqMan qRT-PCR miRNA analysis 
RNA was extracted from the lymph nodes as reported previously by Specht et al [19] 
and from the blood samples using RNABee (Campro Scientific, Veenendaal, The 
Netherlands). Turbo DNAse treatment and qRT-PCR for mature miRNAs were 
performed as described by the manufacturer (Ambion, Foster City, CA, USA). U6 
was used for normalization (∆Ct = CtmiRNA − CtU6) and to check the quality of the 
samples, ie only cases with a cycle threshold (Ct) value lower than 30 were used, 
resulting in a total 
of 28 cases. The primers used were as follows: U6 forward primer: 5’-
tggaacgatacagagaagattagca-3’ and reverse primer 5’-aaaatatggaacgcttcacgaatt-3’. 
Fifteen miRNAs including the chromosome 3 and 13 miR-15-16 clusters (miR-15a, 
miR-15b, miR-16-1, and miR16-2), all members of the miR-17-92 polycistron, and 
five miRNAs known to be highly expressed in B-CLL (miR-181a, miR-155, miR-21, 
miR-101, and miR-150) were analysed by qRT-PCR. Relative expression levels 
were determined by using the formula 2−∆Ct. 
 
RNA in situ hybridization (ISH) 
RNA-ISH was performed as described previously [20,21]. miRNA staining was 
performed using an LNA probe antisense to miR-16, miR-92, miR-155, miR-21, and 
miR-150 (Exiqon, Denmark) in eight CLL cases, according to the manufacturer’s 
protocol. BIC is the primary miRNA (pri-miR-155) transcript that can be processed to 
mature miR-155. DIG-labelled BIC RNA probes were made with the DIG RNA 
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Labeling Kit (Sp6/T7) (Roche, Mannheim, Germany) to detect the full-length primary 
BIC transcript.  
 
Statistical analysis  
The correlation between ZAP-70 and IgH mutational status was analysed with 
Pearson’s chi-square test. The correlation of miRNA expression levels with ZAP-70 
or IgH mutational status was analysed with the unpaired t-test. All p values were 
two-sided and p < 0.05 was considered to be significant. SPSS 14.0 software was 
used for the analysis. 
 
Results 
ZAP-70 expression is associated with IgH mutation status 
IgH analysis was successful for 27 out of 33 CLL lymph node samples. Ten cases 
(37%) contained unmutated IgH genes and 17 cases (63%) carried mutated IgH 
genes (see Supplementary Table 1). Of the blood CLL samples, 18 cases (49%) 
contained mutated IgH sequences. In normal tonsils, ZAP-70 stained intensively 
positive in the T-cells located in the inter-follicular areas, whereas only a few positive 
cells were observed in the follicles. In ZAP-70-positive CLL paraffin tissues, all 
tumour cells, or at least more than 70%, stained positive, whereas in ZAP-70-
negative cases, no recognizable tumour cells stained positive. In total, 16 (49%) of 
the CLL lymph node cases were ZAP-70-positive and 17 (51%) of the cases were 
ZAP-70-negative (see Supplementary Table 1). Combination of the IgH mutation 
status and the ZAP-70 staining in the lymph node revealed that ten of the 13 ZAP-
70-positive cases carried unmutated and three cases carried mutated IgH genes. All 
14 ZAP-70-negative cases carried mutated IgH genes. In 11% of the CLL cases 
(3/27), ZAP-70 status was discordant with IgH mutational status (see Supplementary 
Table 1). Overall, there was a significant correlation between the IgH mutation status 
and the ZAP-70 staining results in CLL lymph node paraffin tissues (p < 0.01).  
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Figure 1. Schematic representation of the miR-17-92 and the miR-15–16 clusters and miRNA 
profile in CLL cases. (A) Schematic representation of the miR-17-92 cluster located on chromosomal 
region 13q31. Schematic representation of the two miR-15–16 clusters located on chromosomal regions 
13q14.3 and 3q26.1. The sequences of the mature miRNAs miR-15a and miR-15b differ at four positions, 
whereas the sequences for miR-16-1 and miR-16-2 are identical. (B) CLL cases from lymph node 
samples show the most abundant expression of miR-150, and intermediate expression levels for miR-16, 
miR-21, miR-92, and miR-155. (C) CLL cases from blood show the most abundant expression of miR-150, 
and intermediate expression levels for miR-16, miR-21, miR-19b, and miR-20a. The difference in the 
relative expression levels between the blood and lymph node samples (see scale on the x-axis) is caused 
by the poorer RNA quality in the paraffin-embedded lymph node samples. 
 
 
Similar miRNA expression pattern in CLL lymph node and blood samples 
Analysis of 15 miRNAs by qRT-PCR revealed the highest expression level for miR-
150 and an intermediate expression level for miR-16 and miR-21 in both lymph node 
and blood CLL. Eight microRNAs (miR-15a, 15b, 17-3p, 17-5p, 18a, 19a, 181a, and 
101) showed very low expression in all samples. In lymph node samples, an 
intermediate expression level was also observed for miR-155 and miR-92a, whereas 
a higher level of expression of miR-19b and miR20a was observed in the blood 
samples (Figure 1). For miR-15, the expression level of the chromosome 3-derived 
miR-15b was higher than that of the chromosome 13-derived miR-15a. The 
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expression level of miR-16 was higher than those of miR-15a and miR-15b (Figure 
1B). However, based on the identical sequences of miR-16-1 and miR-16-2, it is not 
possible to discriminate between the chromosome 3 and 13 copies. 
 
 
Figure 2. Correlation of miRNA 
levels with IgH mutation status. (A) 
The five most abundantly expressed 
miRNAs are shown in relation to the 
IgH mutation status of CLL lymph 
node samples. No difference in the 
expression levels were found for 
these five miRNAs or for the other 
ten miRNAs (data not shown). (B) 
The same five miRNAs are shown in 
relation to the IgH mutation status of 
blood samples. Again, no 
differences were observed in the 
expression levels for these five 
miRNAs or for the other ten miRNAs 
(data not shown). 
 
 
No correlation of the expression levels of the 15 miRNAs with IgH mutation or 
ZAP-70 status 
We did not find a significant correlation between the expression level of any of these 
15 miRNAs and IgH mutation or ZAP-70 status (Figures 2 and 3). A trend of a higher 
expression level of miR-16 (p = 0.06) was observed in unmutated CLL blood 
samples, but not in lymph node samples. Although not significant, miR-150 
expression levels were higher in CLL cases carrying mutated IgH sequences. 
 
 
Figure 3. Correlation of miRNA 
levels with ZAP-70 status. The 
five most abundantly expressed 
miRNAs are shown in relation to 
the ZAP-70 status of CLL lymph 
node samples. No significant 
differences were observed 
between ZAP-70-positive and –
negative cases for any of the 
miRNAs (data for the other ten 
miRNAs are not shown). 
No correlation of the 
expression levels of miR-15a and miR-16 with 13q14 deletion status 
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The 13q14 deletion status was determined in the 37 blood samples by using three 
FISH probes (see Supplementary Table 3). Comparison of the expression levels of 
miR-15a and miR-16 in cases without and with deletions revealed no differences in 
the expression levels for any of the three probes used for the FISH analysis (Figure 





Figure 4. Correlation of miR-15a and miR-16 levels with 13q14 deletion status. (A, B) Correlation of 
the miR-15a and miR-16 levels with the 13q14 deletion status of D13SPRB-1 probe detection. No 
differences were observed between 13q14 undeleted and deleted cases. (C, D) Correlation of the miR-
15a and miR-16 levels with the 13q14 deletion status of D13S319 and D13S25 probe detection. No 
differences were observed between 13q14 undeleted and deleted cases for the miRNAs. undel = no 
deletion; del = deletion. 
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Figure 5. RNA-ISH for miR-150 and BIC/pri-miR-155 in CLL cases. (A) Ki-67 staining is shown in PCs. 
(B, C) miR-150 is weakly expressed in the cells of the PCs. (D, E) BIC/miR-155 positive cells are 
specially localized in the PCs. (F) BIC/pri-miR-155+ cells are large cells with the morphology of pro-




miR-150 and BIC/pri-miR-155 demonstrated an inverse expression pattern in 
PCs and surrounding cells 
ISH analysis of miR-150 and BIC /pri-miR-155 demonstrated a specific expression 
pattern for PCs and surrounding tumour cells. For miR-150, relatively strong and 
homogeneous staining was observed for the neoplastic cells outside the PCs, 
whereas almost no cells within the PCs stained positive. This pattern was observed 
in all five cases that could be analysed (in three cases, the staining failed; Figures 
5B and 5C). For BIC /pri-miR-155, we observed an almost reciprocal pattern, most 
positive cells being localized within the PCs in seven of eight cases analysed (one 
failure). Some of the positive cells could be easily identified as prolymphocytes, 
indicating that these are neoplastic CLL cells (Figure 5F). The smaller cells that 
were positive might represent small CLL cells or T-cells that also accumulate in the 
PCs. Double-staining procedures 
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to identify the nature of these smaller cells failed (data not shown). The number of 
BIC /pri-miR-155-positive cells varied from patient to patient, which was consistent 
with the variance in the size and number of PCs in the individual cases (Figures 5D–
5F). The staining of miR-16, miR-21, miR-92, and miR-155 failed, probably due to 




ZAP-70 and IgH mutation status both represent good prognostic markers and more 
recent reports also indicate that miRNAs might represent valuable prognostic tools. 
Most studies have focused on the analysis of circulating blood cells, whereas lymph 
nodes might better reflect the activation status and function of the neoplastic cells 
than circulating cells. In this study, we analysed blood and lymph node CLL. Both 
the percentage of ZAP-70-positive cases (49%) and the percentage of IgH-mutated 
cases (lymph node 63%; blood 49%) and the correlation are in line with the general 
findings reported by others [5,6,22–25]. Discordance between ZAP-70 and IgH 
mutation status was observed in only three of the 27 cases (11%). These cases 
were ZAP-70-positive but contained mutated IgH genes, including one case with a 
VH3-21 germline sequence. CLL cases with both mutated and unmutated VH3-21 
germline sequences are usually ZAP-70-positive and are characterized by a poor 
prognosis independent of mutation status [26–29]. 
Several studies [10,11,30] showed that miRNA expression is deregulated in CLL 
blood samples and that this may have clinical (prognostic) significance. Calin et al 
[10,11] reported miRNA profiles in CLL blood samples using microarrays and found 
altered expression in comparison to normal CD5+ B-cells. Fulci et al [12] showed 
that miR-16, miR-21, miR-101, miR-150, and miR-155 were the most abundantly 
expressed miRNAs in CLL blood samples by a miRNA cloning approach. Four of 
these miRNAs were also expressed at a higher level in CLL compared with normal 
CD19+ B-cells and normal CD5+, CD19+ cord blood cells as determined by qRT-
PCR. Using qRT-PCR, we found similar high expression of the same miRNAs in our 
cases, with miR-150 being the most abundant in all samples. Our data are quite 
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consistent with those of Fulci et al [12], who also reported high expression levels of 
the same miRNAs. Moreover, we observed a very similar miRNA expression pattern 
in CLL lymph node and blood samples, suggesting that the tumour cells in both 
presentation forms are comparable with respect to miRNA regulation. The difference 
between our data and those obtained by Fulci et al [12], compared with Calin et al 
[10, 11, 30], might be caused by differences in the technical approach. Using 
microarrays, the focus is on differential expression patterns and not on differences in 
absolute expression levels, whereas cloning and qRT-PCR also allow comparison of 
the relative abundance of individual miRNAs. At this moment, 
qRT-PCR specific for mature miRNAs seems to provide more accurate results and 
is considered to be the gold standard [31].  
Of the seven miR-17-92 cluster members, miR-92 was most abundant in lymph 
node, whereas miR-20a and miR-19b were the most abundant miRNAs in blood. 
The other cluster members were expressed only at a very low level. It can be 
speculated that high miR-19b and miR-92 levels are derived from the homologous 
miR-106a–miR-92 cluster located on Xq26.2. However, this does not explain the 
differences between lymph node and blood CLL or the higher expression level of 
miR-20a in the blood samples. Most likely other factors related to processing or 
miRNA stability contribute to the high level of miR-92 or miR-19b and miR-20 in CLL. 
At this moment, it is unclear which genes are targeted by these miRNAs and how 
overexpression of these miRNAs in CLL contributes to lymphomagenesis. Of the 
miR-15–16 clusters present on chromosomes 3 and 13, miR-16-1 and miR-16-2 are 
identical and cannot be detected separately, whereas miR-15a and miR-15b differ in 
four nucleotides (Figure 1). Deletion of chromosome band 13q14 is the most 
frequent aberration found in CLL and is associated with reduced levels of miR-15a 
and miR-16 [9]. In our 37 blood samples, we found 13q14 deletions in about half of 
the cases. Cytogenetic abnormalities of chromosome 3 carrying the second miR-15–
16 cluster are very rare in B-CLL. In our CLL samples, miR-16 levels were higher 
than miR-15a and miR-15b levels, which might suggest that a major part of miR-16 
expression is derived from the primary transcript from chromosome 3. Expression of 
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the chromosome 3 miRNA cluster might also explain the lack of correlation between 
the CLL cases with and without 13q14 deletions.  
Another observation made by Calin et al and Fulci et al is the significant correlation 
of some miRNAs with ZAP-70 status [10–12]. In the first study [10] miR-15a, miR-21, 
and miR-92 were among the miRNAs that could discriminate between the two main 
CLL clusters. In the second study [11], miR-155 was differentially expressed 
between ZAP-70-positive and ZAP-70-negative cases. miR-15a and miR-16 were 
also differentially expressed, but miR-21 and miR-92 were not. In contrast to these 
findings, we did not find any correlation between the expression levels of the 15 
miRNAs and ZAP-70. Some of these discrepancies might be related to the poorer 
quality of the first generation of miRNA microarrays, which were not optimized for 
differences in the hybridization temperatures for each individual miRNA and were 
not specific for the mature miRNA sequences. Fulci et al [12] reported that miR-150 
was differentially expressed between IgH-mutated and IgH-unmutated CLL cases. 
Although we saw the same trend in the CLL samples, the difference was not 
significant in our study.  
Our RNA-ISH indicated that miR-150 was expressed in all tumour cells except the 
PCs, whereas BIC /pri-miR-155 was expressed exclusively in the PCs. These data 
appear to be consistent with the qRT-PCR data of the CLL lymph node samples that 
show a much higher expression level of miR-150 compared with miR-155. These 
results suggest that BIC /pri-miR-155 and miR-150 might play a role in the PCs of 
CLL. In lymph nodes and the bone marrow, PCs are the hallmark of this 
lymphoproliferative disorder and the tumour cells in PCs show a distinct antigen 
expression profile (CD38, Ki67/MIB1, CD23, and MUM1/IRF4 [32,33]). In CLL blood 
samples, we and Fulci et al [12] also demonstrated a very high level of miR-150 
compared with miR-155. The relative abundance of miR-155 compared with miR-
150 is much higher in the lymph node CLL samples. Both BIC /pri-miR-155 and the 
mature form of miR-155 are highly expressed in Hodgkin, primary mediastinal, and 
diffuse large B-cell lymphomas [21,34–36], which supports a role in 
lymphomagenesis. In a transgenic mice model with overexpression of miR-155, 
Costinean et al [37] demonstrated a pre-B-cell proliferation followed by a polyclonal 
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B-cell malignancy. In the transgenic miR-150 mice model, miR-150 controls B-cell 
differentiation by targeting the c-myb transcription factor [38]. Both miR-150 and 
miR-155 play a main role in regulation of the immune response, as demonstrated by 
genetic deletion and transgenic approaches [38–40]. To our knowledge, we have 
shown for the first time the specific miR-150 and BIC /pri-miR-155 expression 
pattern in CLL. Unfortunately, we could not obtain a good RNA ISH signal for the 
mature miR-155 in CLL lymph node cases. This probably reflects the hybridization 
kinetics of the probe, since we also could not obtain a very strong hybridization 
signal for miR-155 in the tumour cells of Hodgkin lymphoma. An alternative 
explanation for the lack of miR-155 signal might be that BIC /pri-miR-155 is not 
processed properly, but this lack of processing has until now only been 
demonstrated in Burkitt lymphoma, which also lacks endogenous expression of BIC 
[41,42]. The low expression of miR-150 in combination with the high expression of 
pri-miR-155 in the PCs needs to be further studied to determine its biological 
relevance in CLL. 
In summary, we observed no difference in the expression levels of our selection of 
15 miRNAs based on ZAP-70 and IgH mutation status. miR-150 is weakly 
expressed in the PCs and strongly in the surrounding cells, whereas BIC /pri-miR-
155 expression is restricted to the PCs of CLL lymph node cases. These findings 
suggest a role for miR-150 and BIC /pri-miR-155 in the regulation of proliferation 
and/or activation of CLL cells. 
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